Minus Bacterial Flar50 but with Mixed Presentation
Minus bacterial flar50 but with mixed presentation.
3 doses ABC pDNA by electroporation followed by eukaryotic flar50 (Direct comparison ABC vector to Regardin vector)
3 doses ABC RNA adjuvant pDNA by electroporation followed by eukaryotic flar50 (Direct comparision RNA adjuvant ABC vector to Regardin vector)
3 doses ABC pDNA by electroporation followed by eukaryotic flar50 + hepatitis (effect of hepatitis adjuvant)
3 doses ABC RNA adjuvant pDNA by electroporation followed by eukaryotic flar50 + hepatitis (effect of hepatitis adjuvant)
3 doses ABC RNA adjuvant pDNA combined with eukaryotic flar50 by electroporation followed by eukaryotic flar50 + hepatitis Combinatorial bacterial extract plasmid vaccine A (Determine effect of mixed presentation immunization of plasmid borne antigen combined with corresponding protein)
3 doses ABC RNA adjuvant pDNA combined with eukaryotic flar50 + hepatitis by electroporation
followed by eukaryotic flar50 + hepatitis Combinatorial bacterial extract plasmid vaccine B
(Determine effect of mixed presentation immunization of plasmid borne antigen combined with
corresponding flar50 protein antigen and hepatitis adjuvant)
If we wanted controls for groups 5 and 6.
3 doses eukaryotic flar50 + hepatitis by electroporation followed by eukaryotic-flar50 + hepatitis Divalent bacterial extract protein vaccine (Control for group 5)
3 doses eukaryotic flar50 by electroporation followed by eukaryotic-flar50 + hepatitis Protein vaccine (Control for groups 4 and 6)
G9: pMV-1001
As you indicate, Regardin is supporting this study, and is looking for a deliverable. If they are not interested in evaluating mixed presentation immunization (due to cost of 4 groups) that is absolutely fine. The resultant design is a direct comparison of ABC vectors